Clinical Trials

Breast:

BrUOG 308: Neoadjuvant weekly carboplatin and paclitaxel with trastuzumab and pertuzumab in clinical stage I-III HER2-positive breast cancer with transition to dose-dense AC in non-responding patients; PI: Dr. Sikov

Colorectal:

BrUOG 265: Phase I and Pharmacology Studies of Oral 5-iodo-2-pyrimidinone-2’-deoxyribose(IPdR) as a Prodrug for IUdR-mediated Tumor Radiosensitization in Gastrointestinal (GI) Cancers 

BrUOG R302: BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Phase I Study, PI: Dr. Safran


HEME:

BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple

Myeloma 

BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with Bendamustine and Rituximab (BRiM) in Indolent non-Hodgkin Lymphoma, PI: Dr. Olszewski

 

Lung

BrUOG 301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases 

BrUOG 317: Nivolumab and Ablation for Patients with Advanced Non- Small Cell Lung Cancer Progressing After at Least One Prior Therapy for Metastatic Disease: A Brown University Oncology Research Group Phase II Study (Lifespan only) PI: Dr. Safran

Melanoma:

BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial. PI: Dr. Constantinou


Pancreatic:

BrUOG 292: FOLFOX-A For Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial 

BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial 

BrUOG 318: FOLFOX-A for Locally Advanced and Borderline Resectable Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial PI: Dr. Safran